10-984 Search Results


zea mays  (ATCC)
90
ATCC zea mays
Zea Mays, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/zea mays/product/ATCC
Average 90 stars, based on 1 article reviews
zea mays - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
pomalidomide  (MedChemExpress)
94
MedChemExpress pomalidomide
Pomalidomide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pomalidomide/product/MedChemExpress
Average 94 stars, based on 1 article reviews
pomalidomide - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
type i human ifn α2a  (R&D Systems)
93
R&D Systems type i human ifn α2a
Type I Human Ifn α2a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/type i human ifn α2a/product/R&D Systems
Average 93 stars, based on 1 article reviews
type i human ifn α2a - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
mrps22  (Proteintech)
93
Proteintech mrps22
a. Example immunoblots showing enrichment of mitochondrial protein and depletion of other compartments (i.e., cytosol and lysosomes) from healthy liver and tumor mito-immunopurified fractions. p53: c-MYC; p53 -/- , Pten: c-MYC; Pten -/- , Kras: Kras G12D ; p53 -/- . Mitochondrial markers: CS (citrate synthase), VDAC, OGDH, CISD1 and SLC25A12. Cytosolic marker: GAPDH. Lysosomal marker: CTSC (cathepsin C). Input designates whole tumor lysate, MITO-IP is the mito-immunopurified fraction. b. Box plots for example proteins in mitochondrial translation (MRPS23), mitochondrial respiratory chain (UQCC3), iron-sulfur cluster assembly (NFS1), TCA cycle (OGDH), fatty acid oxidation (ECHS1), branched chain amino acid (BCAA) catabolism (BCKDHA), glutamine catabolism (GLS2), urea cycle (CPS1); and their expression changes as median normalized z-scores. Median is indicated as line across the box; minimum and maximum values define upper and lower boundaries c. Heatmap for OXPHOS proteins in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select OXPHOS components in c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors (three independent tumors of each genotype) shows enrichment in c-MYC -driven tumors. GAPDH was used as control (non-OXPHOS protein). d. PCA plot for mitochondrial proteome of c-MYC -driven PLC models e. IACS-10759 treatment of c-MYC; p53 -/- and Kras G12D ; p53 -/- tumor bearing mice. IVIS images of pre- and post-treatment tumor bearing mice (two representative mice per group) are displayed. Normalized bioluminescence (BL) flux data post-treatment is plotted as bar graph, showing c-MYC -specific tumor suppressive effect of IACS-10759. P -values are calculated by Mann-Whitney U-test with 95% confidence interval (CI). n.s., not significant. f. Heatmap for mitochondrial translation machinery components in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Columns and rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select mitochondrial translation components in healthy liver tissue, c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors is displayed on the left bottom panel. Middle top panel: Experimental design for generating <t>Mrps22</t> -depleted c-MYC; p53 -/- tumors. IVIS images of representative mice bearing tumors are shown below. Plot on the right displays quantification for control (sgCtrl) and Mrps22 -depleted (sg Mrps22 ) c-MYC; p53 -/- PLC tumors. P -value is calculated by Mann-Whitney U-test with 95% confidence interval.
Mrps22, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrps22/product/Proteintech
Average 93 stars, based on 1 article reviews
mrps22 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
human ifn α2a  (R&D Systems)
93
R&D Systems human ifn α2a
a. Example immunoblots showing enrichment of mitochondrial protein and depletion of other compartments (i.e., cytosol and lysosomes) from healthy liver and tumor mito-immunopurified fractions. p53: c-MYC; p53 -/- , Pten: c-MYC; Pten -/- , Kras: Kras G12D ; p53 -/- . Mitochondrial markers: CS (citrate synthase), VDAC, OGDH, CISD1 and SLC25A12. Cytosolic marker: GAPDH. Lysosomal marker: CTSC (cathepsin C). Input designates whole tumor lysate, MITO-IP is the mito-immunopurified fraction. b. Box plots for example proteins in mitochondrial translation (MRPS23), mitochondrial respiratory chain (UQCC3), iron-sulfur cluster assembly (NFS1), TCA cycle (OGDH), fatty acid oxidation (ECHS1), branched chain amino acid (BCAA) catabolism (BCKDHA), glutamine catabolism (GLS2), urea cycle (CPS1); and their expression changes as median normalized z-scores. Median is indicated as line across the box; minimum and maximum values define upper and lower boundaries c. Heatmap for OXPHOS proteins in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select OXPHOS components in c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors (three independent tumors of each genotype) shows enrichment in c-MYC -driven tumors. GAPDH was used as control (non-OXPHOS protein). d. PCA plot for mitochondrial proteome of c-MYC -driven PLC models e. IACS-10759 treatment of c-MYC; p53 -/- and Kras G12D ; p53 -/- tumor bearing mice. IVIS images of pre- and post-treatment tumor bearing mice (two representative mice per group) are displayed. Normalized bioluminescence (BL) flux data post-treatment is plotted as bar graph, showing c-MYC -specific tumor suppressive effect of IACS-10759. P -values are calculated by Mann-Whitney U-test with 95% confidence interval (CI). n.s., not significant. f. Heatmap for mitochondrial translation machinery components in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Columns and rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select mitochondrial translation components in healthy liver tissue, c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors is displayed on the left bottom panel. Middle top panel: Experimental design for generating <t>Mrps22</t> -depleted c-MYC; p53 -/- tumors. IVIS images of representative mice bearing tumors are shown below. Plot on the right displays quantification for control (sgCtrl) and Mrps22 -depleted (sg Mrps22 ) c-MYC; p53 -/- PLC tumors. P -value is calculated by Mann-Whitney U-test with 95% confidence interval.
Human Ifn α2a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ifn α2a/product/R&D Systems
Average 93 stars, based on 1 article reviews
human ifn α2a - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
pl rpb1 h80y plasmid 10984  (Addgene inc)
N/A
Standard format Plasmid sent in bacteria as agar stab
   Buy from Supplier

Image Search Results


a. Example immunoblots showing enrichment of mitochondrial protein and depletion of other compartments (i.e., cytosol and lysosomes) from healthy liver and tumor mito-immunopurified fractions. p53: c-MYC; p53 -/- , Pten: c-MYC; Pten -/- , Kras: Kras G12D ; p53 -/- . Mitochondrial markers: CS (citrate synthase), VDAC, OGDH, CISD1 and SLC25A12. Cytosolic marker: GAPDH. Lysosomal marker: CTSC (cathepsin C). Input designates whole tumor lysate, MITO-IP is the mito-immunopurified fraction. b. Box plots for example proteins in mitochondrial translation (MRPS23), mitochondrial respiratory chain (UQCC3), iron-sulfur cluster assembly (NFS1), TCA cycle (OGDH), fatty acid oxidation (ECHS1), branched chain amino acid (BCAA) catabolism (BCKDHA), glutamine catabolism (GLS2), urea cycle (CPS1); and their expression changes as median normalized z-scores. Median is indicated as line across the box; minimum and maximum values define upper and lower boundaries c. Heatmap for OXPHOS proteins in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select OXPHOS components in c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors (three independent tumors of each genotype) shows enrichment in c-MYC -driven tumors. GAPDH was used as control (non-OXPHOS protein). d. PCA plot for mitochondrial proteome of c-MYC -driven PLC models e. IACS-10759 treatment of c-MYC; p53 -/- and Kras G12D ; p53 -/- tumor bearing mice. IVIS images of pre- and post-treatment tumor bearing mice (two representative mice per group) are displayed. Normalized bioluminescence (BL) flux data post-treatment is plotted as bar graph, showing c-MYC -specific tumor suppressive effect of IACS-10759. P -values are calculated by Mann-Whitney U-test with 95% confidence interval (CI). n.s., not significant. f. Heatmap for mitochondrial translation machinery components in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Columns and rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select mitochondrial translation components in healthy liver tissue, c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors is displayed on the left bottom panel. Middle top panel: Experimental design for generating Mrps22 -depleted c-MYC; p53 -/- tumors. IVIS images of representative mice bearing tumors are shown below. Plot on the right displays quantification for control (sgCtrl) and Mrps22 -depleted (sg Mrps22 ) c-MYC; p53 -/- PLC tumors. P -value is calculated by Mann-Whitney U-test with 95% confidence interval.

Journal: bioRxiv

Article Title: Tumor Genotype Dictates Mitochondrial and Immune Vulnerabilities in Liver Cancer

doi: 10.1101/2025.09.10.675369

Figure Lengend Snippet: a. Example immunoblots showing enrichment of mitochondrial protein and depletion of other compartments (i.e., cytosol and lysosomes) from healthy liver and tumor mito-immunopurified fractions. p53: c-MYC; p53 -/- , Pten: c-MYC; Pten -/- , Kras: Kras G12D ; p53 -/- . Mitochondrial markers: CS (citrate synthase), VDAC, OGDH, CISD1 and SLC25A12. Cytosolic marker: GAPDH. Lysosomal marker: CTSC (cathepsin C). Input designates whole tumor lysate, MITO-IP is the mito-immunopurified fraction. b. Box plots for example proteins in mitochondrial translation (MRPS23), mitochondrial respiratory chain (UQCC3), iron-sulfur cluster assembly (NFS1), TCA cycle (OGDH), fatty acid oxidation (ECHS1), branched chain amino acid (BCAA) catabolism (BCKDHA), glutamine catabolism (GLS2), urea cycle (CPS1); and their expression changes as median normalized z-scores. Median is indicated as line across the box; minimum and maximum values define upper and lower boundaries c. Heatmap for OXPHOS proteins in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select OXPHOS components in c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors (three independent tumors of each genotype) shows enrichment in c-MYC -driven tumors. GAPDH was used as control (non-OXPHOS protein). d. PCA plot for mitochondrial proteome of c-MYC -driven PLC models e. IACS-10759 treatment of c-MYC; p53 -/- and Kras G12D ; p53 -/- tumor bearing mice. IVIS images of pre- and post-treatment tumor bearing mice (two representative mice per group) are displayed. Normalized bioluminescence (BL) flux data post-treatment is plotted as bar graph, showing c-MYC -specific tumor suppressive effect of IACS-10759. P -values are calculated by Mann-Whitney U-test with 95% confidence interval (CI). n.s., not significant. f. Heatmap for mitochondrial translation machinery components in c-MYC; p53 -/- and Kras G12D ; p53 -/- models. Columns and rows are clustered by hierarchical clustering. Column min and max are distributed across color scale (log scale). Immunoblot for select mitochondrial translation components in healthy liver tissue, c-MYC; p53 -/- and Kras G12D ; p53 -/- tumors is displayed on the left bottom panel. Middle top panel: Experimental design for generating Mrps22 -depleted c-MYC; p53 -/- tumors. IVIS images of representative mice bearing tumors are shown below. Plot on the right displays quantification for control (sgCtrl) and Mrps22 -depleted (sg Mrps22 ) c-MYC; p53 -/- PLC tumors. P -value is calculated by Mann-Whitney U-test with 95% confidence interval.

Article Snippet: Primary antibodies used are Citrate Synthase (Cell Signaling Technology, 14309S), VDAC (Cell Signaling Technology, 4661S), CISD1 (Cell Signaling Technology, 83775S), OGDH (Proteintech, 15212-1-AP), GAPDH (GeneTex, GTX627408), SLC25A12 (abcam, 200201), Beta-actin (GeneTex, GTX109639), Cathepsin C (CTSC, Santa Cruz Biotechnology sc-74590), MRPS35 (Proteintech, 16457-1-AP), MRPS23 (Proteintech, 18345-1-AP), MRPS22 (Proteintech, 10984-1-AP), MRPL3 (Proteintech, 16584-1-AP), NDUFS1 (Proteintech, 12444-1-AP), NDUFB8 (Cell Signaling Technology, 73951S), Total OXPHOS cocktail (abcam, 110411), GATM (Proteintech, 66322-1-Ig), KRAS (Proteintech, 12063-1-AP), Phospho Acetyl CoA Carboxylase (Ser79) Antibody (Cell Signaling Technology, 3661S), PCYT2 (Proteintech, 14827-1-AP), Beta-tubulin (GeneTex, GTX101279), cleaved caspase-8 (Cell Signaling Technology, 8592T), cleaved caspase-3 (Cell Signaling Technology, 9661T), PTEN (Protein, 22034-1-AP), E-cadherin (Cell Signaling Technology, 14472S).

Techniques: Western Blot, Marker, Expressing, Control, MANN-WHITNEY